Genomes are inherently unstable due to the need for DNA sequence variation in the germ line to fuel evolution through natural selection. In somatic tissues mutations accumulate during development and aging, generating genome mosaics. There is little information about the possible causal role of increased somatic mutation loads in late-life disease and aging, with the exception of cancer. Characterizing somatic mutations and their functional consequences in normal tissues remains a formidable challenge due to their low, individual abundance. Here, I will briefly review our current knowledge of somatic mutations in animals and humans in relation to aging, how they arise and lead to genome mosaicism, the technology to study somatic mutations and how they possibly could cause non-clonal disease.
Introduction
Structure and function of all organisms are ultimately determined by their genome, the complete set of species-specific hereditary information. Genomes are sufficiently stable to continuously provide function over the life time. Yet, they are far from immutable. Indeed, mutations in germ line genomes are the substrate of evolution by natural selection and therefore necessary to perpetuate and diversify life. If mutation rates would be zero, all alleles would be fixed and organisms could not adapt [1] . The tendency of genomes to undergo mutations, that is, addition, deletion, or substitution of bits of genetic code, is known as genome instability and the inevitable and irreversible result of errors made during the repair or replication of damaged DNA. Because they generally occur at random, most mutations have adverse effects. Natural selection often eliminates genomes with unfavorable mutations through the demise of their carriers. Some mutations, however, convey positive attributes and will be picked up by natural selection to be perpetuated. It is through mutations that Darwinian selection could lead to increasingly complex genomes and the adaptation of their hosts to the various challenges of a continuously changing environment. possible. It is for this reason that the gradual accumulation of mutations in the genome of somatic cells has been implicated in aging, that is, the time-dependent process of deteriorative change that ultimately brings life to a close [2 •• , [3] [4] [5] . Figure 1 schematically depicts this double-edged sword of genome instability.
Genome instability is known to cause disease in humans, most notably cancer. Cancer arises from single cells as a consequence of repeated cycles of mutagenesis and selection for growth advantage and other attributes that promote tumor progression. However, little is known about the effect of randomly induced mutations on the function of individual cells in a tissue, without selection. Depending on the frequency at which mutations occur and their distribution across the genome of individual cells it is conceivable that the resulting increased tissue mosaicism leads to functional deterioration at old age. The role of somatic mutations in diseases other than cancer will be discussed elsewhere in this special issue. Here, I will discuss how somatic mutations arise and accumulate in aging organisms, leading to genome mosaics, the difficulties in studying somatic mutations and genome mosaicism, how somatic mutations cause cancer and, finally, how random mutations can lead to agerelated functional decline.
Somatic mutations lead to genome mosaicism
The concept that all somatic cells have identical genomes needs to be replaced by a much more dynamic model of an increasingly mosaic genome. The engine behind this is somatic mutagenesis. Somatic mutations are low-frequency events and only directly detectable when they are amplified in a clonal lineage (Figure 2) . Using selectable marker genes in transgenic mice, in the past we have conclusively demonstrated the accumulation of mutations during aging in a variety of organs and tissues, including liver, brain, heart, small intestine, and spleen [6] [7] [8] . The rate of this increase as well as the spectrum of mutations (basepair substitutions, deletions, translocations) differed greatly from organ to organ. For example, while in the intestine point mutations accumulated rapidly to a very high level at old age, in heart and liver also the frequency of genome rearrangements was significantly higher at old age [8] .
Over time, accumulating somatic mutations essentially turns an aging tissue into a mosaic of cells with different genotypes. Owing to the emergence of powerful new methods for analyzing copy number variation (amplifications and deletions) of DNA segments defined by single nucleotide polymorphisms, deletions were observed in blood and other tissues of humans and mice [9 • ,10 • ]. Such deletions must find their origin in the creation of somatic subpopulations of cells due to expansion of a single, de novo mutation. Indeed, an agerelated accumulation of clonally expanded, copy number variants has been found [11] [12] [13] . Similarly, the age-related emergence of genomic differences between monozygotic twins who were identical at early age has been observed and interpreted as originating from somatic mutation [14] . These findings are highly likely to be only the tip of an iceberg because even the most recent 1 million-probe array cannot detect deletions smaller than ~10 kb by comparative genomic hybridization (CGH) [15] . Moreover, mutations occurring in less than ~10% of all cells are no longer detectable. Hence, direct methods can only detect sizable somatic genome alterations and then only as clonally amplified mutations affecting a substantial fraction of the tissue or cell population.
There is also a large body of evidence that chromosomal aberrations, which are microscopically detectable using fluorescence in situ hybridization (FISH), capable of detecting alterations affecting no less than 1-5 million basepairs, accumulate in blood lymphocytes of both humans and mice [16 • ,17] . Especially aneuploidy, that is, the loss or gain of whole chromosomes resulting in an abnormal numerical karyotype, appears to be remarkably high, even in postmitotic tissue [18, 19] . Chromosomal aneuploidy is a hallmark of pathological conditions and a causal factor of birth defects and cancer. Using advanced FISH technology it has been shown that in the developing nervous system of humans and mice the frequency of aneuploid cells is as high as 33% for all chromosomes combined [20,21 • • ] . This extraordinary high level of genome instability during development is in keeping with observations of whole-chromosome aneuploidy and segmental deletions and duplications in individual blastomeres of cleavage-stage embryos after in vitro fertilization (IVF) [22 • • ] . Interestingly, although IVF success rates are typically in the order of 25%, in only 9% of these embryos was such genomic variation not present. This indicates extensive selection of non-mutated or less severely mutated blastomeres in the early embryo, which also suggests that the observed high frequency of aneuploidy during development can decline thereafter (through selection) and not be fatal. Indeed, In human or mouse adult brain, in which only few chromosomes were analyzed by interphase FISH, aneuploidy frequencies were found to be much lower than in developmental mouse brain, that is, ~10% for all chromosomes combined. However, this is still high and we have shown that in the mouse brain aneuploidy accumulates with age, up until about 50% for all chromosomes combined in 28-month-old animals [19] . Somatic mutation rates differ among different types of genomic sequence. Indeed, in regions containing repeat elements, such as mini-satellites and micro-satellites, retrotransposons and telomeres, spontaneous mutations can occur at a much higher rate than in single-copy regions. Mutations at microsatellite loci have been found to occur at rates as high as 1 × 10 −2 per locus in human blood and increase with age [23] . Retrotransposition has been observed in rodent brain in vivo [24] and deep sequencing has revealed insertions of retrotransposons in Drosophila and human brain [25, 26] . In yeast, during replicative aging, increased retrotransposition has been observed concomitant with a loss of nucleosomes, a cause of aging in budding yeast [27] . Telomeres, regions of repetitive DNA protecting chromosome ends from deterioration, significantly shorten with age in mammalian cells and tissues [28] , in part due to the end replication problem [29 • • ].
In conclusion, somatic mutations accumulate with age in a tissue-specific manner, turning tissues into genome mosaics. Direct evidence for such mosaics has been obtained only for clonally amplified structural variations greater than ~10 kb. For elucidating the complete landscape of somatic mutations over the life time of an individual new, advanced methodology is necessary.
Single-cell genomics to determine the in vivo landscape of somatic mutations
Rapid progress in nucleotide sequencing technology [30, 31] now allows the detection of even minute post-zygotic mutational differences between the genomes of monozygotic twins [32] . However, as we have seen, apart from very large chromosomal alterations, mutations present in less than ~10% of all cells in a tissue cannot be detected by direct analysis, but requires selectable markers. In the above discussed examples somatic mosaicism could only be detected because the mutation occurred early during development and/or aging, thereby eventually comprising a sizable fraction of cells. Such mutations are the tiny tip of what surely must be a gigantic iceberg of mutations, many unique for a particular individual cell. Therefore, we have no real insight into the true number of genome variants in the different cells comprising a tissue. Indeed, virtually our entire knowledge of the genome has come from studying cells in bulk, that is, as mixtures of cells. In principle one could detect somatic mutations in DNA from bulk cell populations by sequencing thousands of times across the genome and call all possible variants of the consensus sequence. In practice this would be very inefficient and expensive, and also essentially constrained by the high rate of sequencing errors, which can amount to close to 1% [33, 34] . Genuine somatic mutations cannot be distinguished from sequencing errors, which are scattered through the reads (Figure 3 ). The problem is very similar to the situation in tumors in which we are also unable to glimpse behind the relatively few mutations common to all or most cells in that tumor [35] . One possible solution for this problem is to sequence single cells after whole genome amplification and analyze combinations of mutations in an integrated manner. The latter is essential for assessing if random mutations are truly capable of adversely affecting cellular function (see below).
We recently developed a method to determine somatic mutation frequencies and spectra across the genome of a tissue or cell population by sequencing a representative number of single cells after whole genome amplification [36 • ]. After amplification, mutations unique for each cell will now occur in half of all sequencing reads for a particular locus. Only half of all reads, because a true mutation will affect one allele only, since it is highly unlikely that the other allele will also be hit at that same site (Figure 3) . The single-cell protocol we developed was validated by testing if an elevation in mutation frequency in Drosophila S2 cells or mouse embryonic fibroblasts could be detected after treatment with a powerful mutagen (i.e., ethylnitrosourea; ENU). The results indicated a dramatically higher level of mutations in the exposed cells as compared to untreated control cells [36 • ]. This is expected because ENU is a powerful mutagen. The exposed cells also revealed increased levels of A:T → T:A mutations, which are known to be highly enriched following treatment with alkylating agents.
While in these initial experiments we only called single nucleotide variants (i.e., point mutations), it is possible to also identify structural variations in this way using a so-called paired-end mode of sequencing [30,37 • ]. When DNA fragments of a particular size are sequenced from both ends the paired reads should be positioned at a known distance from each other when aligned to a reference sequence (Figure 4) . If the distance between the read pairs differs from the distance between the mapped positions on the reference genome, then a deletion or insertion is implied. It is also possible that one of the two read pairs maps to another chromosome, indicating a chromosomal translocation. Polymorphic variants with the reference genome are subtracted by always including a sequencing run from the nonamplified, whole tissue or whole cell population. The procedure allows us to call all possible somatic mutations present in a particular single cell.
Genome amplification is often considered a major source of false positive mutations. For example, the most popular whole genome amplification method is multiple displacement amplification (MDA), which has been shown to cause false positive inversion mutations [38] . However, for point mutations such artifacts are unlikely. An error introduced early in MDA would be found in only 12.5% of the sequencing reads at a given locus in a diploid cell on average [39] . Since as shown in Figure 3 true somatic mutations should affect one allele and therefore need to be found in 50% of the reads, amplification errors are easily filtered out. Also, recent developments in whole genome amplification have now greatly diminished concerns about amplification artifacts [40] and, albeit more difficult than SNVs, structural variations can be detected in single cells [30] . Indeed, recent work demonstrated the detection of copy number variation in single human neurons after whole genome amplification [10 • ].
The great advantage of opening up next-generation sequencing to the analysis of somatic mutations is that, for the first time, all possible mutations, including low-abundant mutations, can be analyzed on a genome-wide basis. The latter is critically important because mutations are not uniformly distributed across the genome, but subject to significant constraints, including, for example, chromatin structure, transcription, the local structure of the genomic regions studied (e.g., repeats versus single-copy DNA) [41] . To systematically determine complete mutation spectra for a large number of single cells or nuclei from multiple somatic tissues at different age levels should allow us to unravel the impact of genome mosaicism on health and disease. Below I will illustrate how somatic mutations are responsible for cancer, a major age-related disease, but possibly also for non-cancer, degenerative aspects of the aging process.
Somatic mutations can cause both cancer and aging
While cancer can occur also in young people, the incidence and mortality of most cancers increases exponentially with age [42] . While other factors, such as age-related changes in immune function [43] , apoptosis or autophagy [44] , may also contribute, the mechanistic basis of the relationship between cancer and aging most likely involves a lifetime of DNA mutation accumulation as a natural consequence of inevitable errors during repair or replication of damaged DNA [5, 45] . Indeed, DNA damage is ubiquitous, as a result of both endogenous processes, such as hydrolysis, oxidation and alkylation, and environmental genotoxicants [46] . While most of that damage is efficiently repaired, errors during replication and repair are inevitable and irreversible once the original template is lost. Exposure to environmental mutagens is known to shift the age-incidence curves of cancer towards accelerated risk, most likely by increasing mutation rates. The best example is tobacco smoke which, increases cancer risk in a clear dose-response relationship [47, 48] .
Indeed, lung tumors from smokers have an average mutation frequency more than 10-fold higher than lung tumors from non-smokers [49] .
The reason that the accumulation of somatic mutations with age is so readily adopted as a likely cause of the age-related increase in cancer risk is the universally accepted model of cancer initiation and progression. This model, first proposed by Fearon and Vogelstein in 1990 for colorectal cancer [50 • ], posits a series of sequential mutations that first provide a selective growth advantage to the target cell(s) and subsequently other favorable attributes, such as the capacity to invade tissues, suppress immune responses and inactivate other antitumor responses, such as apoptosis. Eventually, mutations are also responsible for resistance to anti-cancer drugs. Each mutation is followed by clonal outgrowth in which a particularly advantageous mutation is selected. The eventual malignant neoplasm shows a mutation spectrum that reflects its clonal history, but also contains so-called passenger mutations, that is, mutations that were not selected because of a clonal growth advantage and therefore did not contribute to cancer development. Many of those mutations had been accumulated during development and aging before tumor initiation [51] . The tumor mutation spectrum often also reveals the original mutagens responsible for the tumor-inducing mutations, for example, C:G to A:T in lung tumors from smokers and C:G to T:A mutations in the same tumor type from non-smokers. In this way, initially rare somatic mutations can eventually become predominant through natural selection.
It is now clear that the number of somatic mutations in tumors is significantly higher when the tumor was derived from an old patient as compared to a young one [52, 53] . Indeed, mathematical modeling strongly suggests that half or more of somatic mutations in tumors arise before initiation of the tumor, that is, during development and aging [51] . We still know very little about the mutational heterogeneity of normal tissues. Also intratumor variation in mutation spectra remains an enigma [35] . Nevertheless, the concept of age-related mutation accumulation to explain the age-related increase in cancer is straightforward. Such mutationdriven loss of proliferative homeo-stasis, giving rise to hyperplasias, benign neoplasms and malignant neoplasms, is a major component of the aging phenotype and likely to be causally related to age-related mutation accumulation in cells from self-renewing tissues [54] . By contrast, a causal role of mutations in tissue functional decline would rely on a cumulated mutation load in many or most cells of an organ or tissue that is high enough to have adverse effects without selection.
Recently, a series of observations revealed that defects in genome maintenance pathways cannot only lead to increased cancer but also to multiple symptoms of cell and tissue degeneration that are normally only seen at old age. For example, heritable mutations in RecQ helicase genes cause segmental progeroid syndromes, such as Werner Syndrome [55] . Also mice harboring defects in DNA double-strand break repair or nucleotide excision repair display signs of premature aging, sometimes at very early age [56] . While this strongly suggests that DNA damage and/or mutations are critical factors in aging and its disease sequelae, there is now also recent evidence that cancer survivors who have been treated with DNA damaging chemotherapeutic agents display multiple symptoms of premature aging. Indeed, while in the past surviving cancer was relatively rare, this has now become more common. Interestingly, an ever growing number of adults who survived childhood cancer, is now diagnosed with health problems common to much older people, such as frailty, low muscle mass, slow walking speed, weakness and memory impairment [57 • ]. While this could be, at least in part, an effect of the cellular responses to DNA damage, such as apoptosis and cellular senescence, the secondary cancers that are also observed [58] point towards DNA mutations as another possible cause.
As described in more detail by Erickson elsewhere in this special issue, both de novo and post-zygotic mutations are increasingly found to contribute to human disease, with the former now a known cause of autism [59, 60] and the latter already known from disorders where the manifestations are readily seen, for example, the skin in type I neurofibromatosis [61] . Clearly, somatic mutations occurring early during development are likely to have a greater effect on phenotype expression than mutations occurring later and virtually all examples derive from clonal lineages with the disease-causing somatic mutation occurring during embryogenesis. In many cases the critical somatic mutation is a second mutation turning a recessive germ line mutation in one allele into a dominant phenotype after somatic inactivation of the other allele [62] . An interesting example of genome mosaicism as a cause of neurodegenerative disease is the observed somatic mutation in the presenilin-1 gene in a sporadic early-onset patient with Alzheimer's disease [63] .
There is currently no direct evidence that somatic mutations causally contribute to aging and late-life disease other than cancer. Somatic mutations have been found in atherosclerotic plaques, but their causal role in atherogenesis and vascular disease development is uncertain [64] . Indeed, the functional impact of somatic mutagenesis other than through clonal amplification is presently unclear. The question is whether random mutations affecting single genes at low frequency can have an effect at the tissue level when not amplified through clonal outgrowth. While the current lack of detailed information about the landscape of somatic mutations in aged individuals prevents answering this question, it is certainly conceivable that random mutations affect cellular function. Indeed, function is not provided by single genes but through often extensive, functional networks consisting of genes and their regulatory sequences. Together, this would comprise a sizable genomic target for mutation. Each and every mutational hit in a sequence that is part of this network has the potential to adversely affect function.
For example, for a typical differentiated human cell we can conservatively estimate that about 1% of the diploid genome (60 Mb) is functional [65 •• ] . While the germline de novo mutation frequency in humans is only about 60 new mutations per genome (1.2 × 10 −8 /bp or ~0.01/Mb [66] ), somatic mutation frequencies are much higher than germline mutation frequencies [67] . Indeed, the mutation frequency in human tumors that have been subjected to whole genome sequencing was found to vary from about 0.1/Mb to almost 200/Mb [52] , with the median at about 6/Mb. As mentioned above, many mutations found in tumors have accumulated in the normal cells before tumor initiation, which is the most likely reason that tumors from children contain fewer mutations than tumors from adults or older individuals [51, 68] . Our own unpublished data, obtained using the new, single-cell sequencing procedure (see above), indicate about 1 single nucleotide variant (SNV) per Mb in liver hepatocytes from 27-month old mice. This excludes structural variants (SVs), which are much less frequent, but likely to have more dramatic effects. In the ~60 Mb of the genome that presumably is functional in a differentiated cell, an SNV frequency of about 1/Mb would then result in about 60 mutations. A fraction of these mutations could potentially adversely affect functional networks in that cell. Our data indicate that 5% of all somatic mutations in exons are nonsense mutations, with about 60% missense mutations (unpublished). This fraction of non-synonymous mutations is much higher than that in the germline genome because of the absence of selection. Including the SVs, which also accumulate with age [6] , it certainly is conceivable that random mutations accumulating during aging do have functional effects other than clonal disease.
Summary and future prospects
Like germ line mutations, somatic mutations are part of the logic of life. But while germ line mutagenesis is a sine qua non for the perpetuation of life, mutations in the soma are not needed and could very well lead to an error catastrophe, as originally proposed by Orgel for proteins [69] . In principle, evolution could postpone catastrophe by evolving ever more sophisticated genome maintenance systems to gradually increase species-specific longevity [70 • ]. However, evolution by natural selection is a process not conducive to maximization of life span beyond the age of first reproduction [71] .
Somatic mutation has been coopted during evolution to generate the means of creating immunoglobulin diversity, a critical factor in the immune response, and has also been suggested to play a role in generating diversity in the brain to broaden the spectrum of phenotypes that can originate from a single genome [72] . However, somatic mutations are unlikely to play a major role in human physiology and most of them are harmful and could contribute to aging.
In summary, somatic mutations appear to be much more frequent than initially thought, reactivating original ideas about the causes of aging and age-related disease [2 •• ,3] . Indeed, those hypotheses can now be more firmly outlined. As schematically depicted in Figure 5 , mutations inevitably and irreversibly accumulate during development and aging. They become manifest as clonal lineages causing cancer and other cell proliferative disorders. However, conceivably when a critical level is reached, mutations begin to adversely affect cell-specific functional networks, resulting in a mosaic of cells harboring different mutation loads and varying levels of functional deficiency. Depending on the severity of the mutation load, the cell type, genetic and environmental factors, this would lead to functional decline, disease and, possibly, aging. The genome harbors all the instructions for providing function to the somatic cells of an organism. Random alterations in its information content in the germ line drive evolutionary change, while similar changes in the somatic cells could be the cause of aging. Schematic depiction of mutation accumulation during development and aging. Cancercausing mutations (red check mark) are actively selected for, resulting in the clonal development of a tumor (beige). Occasionally, a mutation is subject to genomic drift (green check mark) and also leads to clonal amplification (green). Single-cell analysis is required for detecting low-abundant, random mutations. The A > G mutation (red check mark) can only be distinguished from sequencing errors after singlecell, whole genome amplification when it shows up in ~50% of the reads (red; one mutated allele). Polymorphic variants (SNPs; blue) are also observed in the unamplified control DNA extracted from the bulk cell population. SNPs are variants between the genome of our cells and the reference genome. They are electronically discarded. Paired-end sequencing allows the identification of a large variety of structural variation as discrepancies after aligning the sequencing reads to the reference genome. 
